Novavax, Inc. (NASDAQ: NVAX) Has Another Chance To Impress You

Currently, there are 118.79M common shares owned by the public and among those 111.93M shares have been available to trade.

Insiders at the company have transacted a total of 32 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 21 of these insider trades were purchases, accounting for 72,911 shares. Insider sales of the common stock occurred on 11 occasions, with total insider shares sold totaling 20,087 shares.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

However, the script later moved the day high at 4.3400, up 2.98%. The company’s stock has a 5-day price change of 10.37% and -38.15% over the past three months. NVAX shares are trading -13.54% year to date (YTD), with the 12-month market performance down to -57.57% lower. It has a 12-month low price of $3.53 and touched a high of $11.36 over the same period. NVAX has an average intraday trading volume of 1.08 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.97%, -12.75%, and -39.04% respectively.

Institutional ownership of Novavax, Inc. (NASDAQ: NVAX) shares accounts for 57.48% of the company’s 118.79M shares outstanding.

It has a market capitalization of $492.98M and a beta (3y monthly) value of 1.54. The earnings-per-share (ttm) stands at -$6.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.26% over the week and 5.67% over the month.

Analysts forecast that Novavax, Inc. (NVAX) will achieve an EPS of $Dynavax Technologies Corporatio for the current quarter, $12.82 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $ETF Opportunities Trust T-Rex 2 while analysts give the company a high EPS estimate of $Evaxion Biotech A/S. Comparatively, EPS for the current quarter was $NOVONIX Limited – American Depo a year ago. Earnings per share for the fiscal year are expected to increase by 49.98%, and 82.76% over the next financial year.

Looking at the support for the NVAX, a number of firms have released research notes about the stock. B. Riley Securities stated their Buy rating for the stock in a research note on August 09, 2023, with the firm’s price target at $15.

Most Popular

Related Posts